About us


  • Year PELI IRB was established: CY 2012
  • PHREB Registration No. : L3-2018-043-02
  • PHREB Level of PELI IRB: Level 3
  • Effective Date: July 16, 2018
  • Expiry Date: July 15, 2021


                What are Clinical Trials?

  • Clinical trials are research studies that explore whether a medical strategy, treatment, or device is safe and effective for humans. These studies also may show which medical approaches work best for certain illnesses or groups of people.

                Institutional Review Board (Definitions)

  • INSTITUTIONAL REVIEW BOARD – An independent body constituted of medical, scientific, and non-scientific members, whose responsibility is to ensure the protection of the rights, safety and well-being of human subjects in a trial by, among other things, reviewing, approving, and providing continuing review of trial protocol and amendments and of the methods and material to be used in obtaining and documenting informed consent of the trial subjects. ICH-GCP E6 (R1)Other Names of Institutional Review Boards:
    • Ethics Review Committee
    • Institutional Ethics Review committee
    • Research Ethics Board
    • Ethical Review Board

    Brief History of Peregrine Eye and Laser Institute – Institutional Review Board

    Since its inception, research has been a key ingredient in Peregrine Eye and Laser Institute’s (PELI) aspirations to provide excellent, modern, evidence-based quality care to its patients.  Only through responsive ethical researches can up-to-date interventions and better patient options become readily available to improve health outcomes.  Without the benefit of researches, Filipino patients would suffer the indignity of having to settle for prehistoric modes of treatment and stagnant choices.  This is one of the prime motivations in the establishment of the PELI Institutional Review Board in CY 2012.  The IRB has provided ethical guidance and patient safeguards in the pursuit of responsive clinical researches that benefit not only PELI patients but all Filipinos nationwide.  It is also pioneering in that it is one of a few institutional review boards outside the confines of a hospital setting.  PELI researches have contributed positively to the entry of innovative solutions in the country as well as improved patient outcomes for many Filipinos.

    With the growing complexities of numerous diseases, the evolution of basic sciences in the understanding of these disorders, and the endless possibilities of interactions between and among disease entities, the approach of PELI must equally evolve to be more holistic in order to serve the needs of its patients fully.  It must also be facilitative in assessing innovative new medicines, medical supplies, and therapeutic interventions.  These consequently place a burden on the institution to do more researches to remain true to its goal for its patients.

    The value of being patient centric is at the heart of PELI.  All researches should be designed to improve the quality of lives of patients, so too should these researches assure the safety and welfare of research participants, especially those trying out innovative treatment options.  Patient rights must be continuously upheld in line with local and international ethical and regulatory standards.

    In this regard, the IRB must also be responsive and must evolve to safeguard the interests of patients and research participants, among others.  It should remain independent, well represented, and compliant with existing non-discriminatory public policies and regulatory standards.  To this end, the IRB shall be improved and developed to be able to continuously achieve its duty to facilitate innovative researches without compromising ethics, patient safety, welfare and rights. PELI-IRB SOP Chap 1-Introduction


    Staff Secretary: Myren C. Tagra
    PELI IRB trunk line: (+63) 2-8-8900-0115 loc. 113
    PELI IRB e-mail address:
    PELI IRB address: PELI-IRB Rm., 50 Jupiter St., Brgy. Bel-Air, Makati City.